13F Holdings
中文EN

LXEO Lexeo Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1907108 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-0.3%
TTM EPS YoY54.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-62.4%
ROA-54.3%
ROIC (approx.)-88.6%
Asset turnover—

Leverage & solvency

Liabilities / assets11.2%
Debt / equity0.00x
Current ratio8.69x
Interest coverage-1,807.43x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue———$654,000
R&D expense$63.80M$74.09M$53.13M$49.16M
SG&A expense$45.46M$31.68M$15.38M$12.00M
Operating income-$109.26M-$105.77M-$68.51M-$60.51M
Interest expense$95,000$137,000$205,000$91,000
Pretax income-$99.67M-$98.44M-$66.39M-$59.28M
Income tax$0$0——
Net income-$99.96M-$98.33M-$66.39M-$59.28M
EBITDA-$108.99M-$105.46M-$68.24M-$60.39M
EPS (basic)-1.86-3.09-12.40-36.36
EPS (diluted)-1.86-3.09-12.40-36.36
Weighted avg. shares (diluted)53.65M31.79M5.35M1.63M
Balance sheet
Cash & equivalents$63.00M$38.27M$124.72M$80.59M
Short-term investments$118.77M$86.50M——
Current assets$188.39M$126.12M$124.29M$80.05M
PP&E, net$1.14M$1.03M$1.06M$998,000
Total assets$268.69M$146.94M$139.81M$97.08M
Current liabilities$16.81M$22.85M$17.24M$14.35M
Total liabilities$22.02M$30.10M$26.27M$25.00M
Shareholders' equity$246.67M$116.84M$113.53M-$112.95M
Shares outstanding73.00M33.07M26.65M1.61M
Cash flow statement
Operating cash flow-$98.56M-$81.15M-$59.50M-$54.56M
Capital expenditure$397,000$481,000$115,000$672,000
Free cash flow-$98.96M-$81.63M-$59.61M-$55.23M
Investing cash flow-$90.25M-$94.08M-$165,000-$901,000
Financing cash flow$216.79M$88.78M$103.79M$189,000
Depreciation & amortization$268,000$304,000$271,000$120,000
Stock-based compensation$12.13M$12.47M$3.04M$1.78M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.